# 12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe

> **NCT00525824** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1743 (actual)

## Conditions studied

- Hypercholesterolemia
- Coronary Heart Disease
- Atherosclerosis

## Interventions

- **DRUG:** Rosuvastatin (Crestor)
- **DRUG:** Ezetimibe
- **DRUG:** Simvastatin

## Key facts

- **NCT ID:** NCT00525824
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 1743 (ACTUAL)
- **Last updated:** 2011-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00525824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00525824, "12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00525824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*